Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio Growth (3y) (2016 - 2026)
Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 28.11% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 29.47% |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 40.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.09% |
| Dec 31, 2025 | 733.63% |
| Sep 30, 2025 | 49.18% |
| Jun 30, 2025 | 55.27% |
| Mar 31, 2025 | 27.56% |
| Dec 31, 2024 | 38.75% |
| Sep 30, 2024 | 20.85% |
| Jun 30, 2024 | 32.65% |
| Mar 31, 2024 | 40.08% |
| Dec 31, 2023 | 43.46% |
| Sep 30, 2023 | 42.33% |
| Jun 30, 2023 | -1.59% |
| Mar 31, 2022 | -64.92% |
| Dec 31, 2021 | -174.25% |
| Sep 30, 2021 | 77.86% |
| Jun 30, 2021 | 71.46% |
| Dec 31, 2020 | 62.62% |
| Sep 30, 2020 | 68.53% |
| Jun 30, 2020 | 71.06% |
| Dec 31, 2016 | -483.33% |